Researchers highlighted on Monday that certain genes may help identify patients with obesity who are most likely to respond strongly to Novo Nordisk A/S’s (NYSE:NVO) weight-loss drug Wegovy ...
Novo Nordisk’s blockbuster GLP-1 analog Wegovy (semaglutide) can maintain meaningful weight loss for up to four years and improve cardiovascular health regardless of the amount of weight lost, ...
Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.
LONDON (Reuters) -Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the drugmaker's case to insurers and ...
Patients using Novo Nordisk’s NVO NONOF obesity treatment, Wegovy, have reportedly maintained an average weight loss of 10% over a four-year period, as per data revealed by the company on Tuesday.
LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday. Novo ...